

March 17, 2022

NEWS RELEASE

Company: KYORIN Holdings, Inc.
Representative: Yutaka Ogihara
Representative Director, President
(Securities Code: 4569, TSE 1st Sec.)
Contact: Yoshinori Tanifuji
Director, Corporate Planning
Telephone: (0)3-3525-4707

**KYORIN and Nanjing Neiwa Faith Signed License Agreement
for Lascufloxacin in China**

KYORIN Holdings, Inc. today announced that KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President & CEO: Shigeru Ogihara, "Kyorin"), a wholly owned subsidiary of KYORIN Holdings, Inc signed a license agreement with Nanjing Neiwa Faith Co., Ltd. (Head office: Nanjing, China, President & CEO: Xu Liang, "Nanjing Neiwa Faith") to grant Nanjing Neiwa Faith an exclusive license to develop and commercialize Lascufloxacin, an oral novel quinolone antibacterial drug in China.

Lascufloxacin is a novel quinolone antibacterial drug manufactured by Kyorin as a new therapeutic agent for respiratory and ENT infections. In Japan, Kyorin launched the product under the name of "Lasvic[®] Tablets 75 mg" in January 2020.

Kyorin is developing activities to provide solutions in infection-related fields in Japan. By continuously providing the latest information in the respiratory and otolaryngology fields, which are the priority areas of Kyorin, Kyorin will contribute to further treatment of infectious diseases, promote this drug in China through the alliance with Nanjing Neiwa Faith, and continue to develop global licensing activities actively.

The impact of this transaction on business performance for the fiscal year ending March 2022 is to be negligible.

About Nanjing Neiwa Faith Co., Ltd.

Foundation: 2020
President & CEO: Xu Liang
Annual Sales: RMB 1.2 billion (2021)
Employees: 802 (as of December 31, 2021)
Overview: Nanjing Neiwa Faith has its head office and factory in Nanjing, China, and introduces pharmaceutical products from Japan and sells them in China. Approximately 600 sales representatives engage in sales activities focused on approximately 5,300 hospitals in major cities in China.